Vaccines produced by Pfizer/BioNTech and Moderna could be given approval for market by mid-December, European Commission President Ursula von der Leyen said Thursday.
“If all proceeds with no problems, EMA (European Medicines Agency) tells us that the conditional marketing authorization for BioNTech and Moderna could happen as early as the second half of December 2020,” von der Leyen said.
She added that this is the “very, very first step to be able to go on to the market” with both of these vaccines.
The Commission president said that all vaccines are properly assessed by the EMA and authorized in cooperation with other authorities. They worked closely with the FDA on authorization of the BioNTech and Moderna vaccines.
The European Commission now has contracts with Pfizer/BioNTech, Curevac, AstraZeneca, Johnson & Johnson and Sanofi and continue negotiations with Moderna. They are also still in talks with Novavax.